Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - OtherShares OutstandingShares Outstanding
Ratios

Pliant Therapeutics (PLRX) Accumulated Depreciation & Amortization (2019 - 2026)

Pliant Therapeutics has reported Accumulated Depreciation & Amortization over the past 8 years, most recently at $10.4 million for Q1 2026.

  • Quarterly Accumulated Depreciation & Amortization fell 7.25% to $10.4 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $10.4 million through Mar 2026, down 7.25% year-over-year, with the annual reading at $10.9 million for FY2025, 0.57% up from the prior year.
  • Accumulated Depreciation & Amortization was $10.4 million for Q1 2026 at Pliant Therapeutics, down from $10.9 million in the prior quarter.
  • Over five years, Accumulated Depreciation & Amortization peaked at $12.0 million in Q3 2025 and troughed at $5.5 million in Q1 2022.
  • The 5-year median for Accumulated Depreciation & Amortization is $9.2 million (2024), against an average of $9.0 million.
  • Year-over-year, Accumulated Depreciation & Amortization soared 42.29% in 2022 and then decreased 7.25% in 2026.
  • A 5-year view of Accumulated Depreciation & Amortization shows it stood at $6.8 million in 2022, then rose by 26.91% to $8.7 million in 2023, then grew by 24.48% to $10.8 million in 2024, then grew by 0.57% to $10.9 million in 2025, then fell by 3.96% to $10.4 million in 2026.
  • Per Business Quant, the three most recent readings for PLRX's Accumulated Depreciation & Amortization are $10.4 million (Q1 2026), $10.9 million (Q4 2025), and $12.0 million (Q3 2025).